OpenNashEarnings

Vertex Pharmaceuticals (VRTX) · Biotechnology

Vertex Pharmaceuticals Q2 2026 earnings: summary, key numbers & outlook

Results filed 3 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Vertex added rare endocrine disease as a fifth pillar by agreeing to acquire Crinetics, while ALYFTREK, CASGEVY and JOURNAVX broadened its commercial base beyond TRIKAFTA.

Vertex's newer medicines gained ground. ALYFTREK is now reimbursed in 25 countries, and new Phase 3 data in children aged 2 to 5 support regulatory filings. The FDA approved CASGEVY for children 2 and older, which may make about 5,500 more patients eligible. JOURNAVX filled about 535,000 prescriptions in the quarter and gained Medicare Part D coverage at two more major PBMs.

Management is diversifying beyond cystic fibrosis. The pending Crinetics acquisition would add rare endocrine disease as a fifth pillar, and povetacicept faces a November 30, 2026 FDA decision in IgAN as the first step in a nephrology pillar. The tension is execution. Vertex must close the deal in the third quarter, launch new products, and keep a large pipeline on schedule while updating guidance after closing.

No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.

Key numbers

Total revenue · GAAP
$3.33 billion

up 12% from the second quarter of 2025

Net income · GAAP
$1.1 billion

compared to $1.0 billion in the second quarter of 2025

Diluted EPS · GAAP
$4.31

up from $3.99 a year ago

Diluted EPS · non-GAAP
$4.73

up from $4.52 a year ago

Operating income · GAAP
$1.2B

up from $1,151.1 a year ago

Segment or metricValueChange
TRIKAFTA/KAFTRIO$2.5Bdown from $2,551.1 a year ago
ALYFTREK$573.6Mup from $156.8 a year ago
CASGEVY$76 million78% sequential growth and 151% growth from the second quarter of 2025
JOURNAVX$50 million71% sequential growth; more than quadrupled from $12 million a year ago
JOURNAVX prescriptions filledapproximately 535,000approximately 900,000 in the first six months of 2026
Where each number comes from
  • Total revenue: “Total revenue increased 12% to $3.33 billion compared to the second quarter of 2025, primarily driven by the continued performance of cystic fibrosis (CF) therapies”
  • Net income: “GAAP and non-GAAP net income were $1.1 billion and $1.2 billion, respectively, compared to $1.0 billion and $1.2 billion, respectively, for the second quarter of 2025”
  • Diluted EPS: “Net income per diluted common share: GAAP | $4.31 | $3.99 | $8.33 | $6.48 Non-GAAP | $4.73 | $4.52 | $9.21 | $8.58”
  • Diluted EPS: “Net income per diluted common share: GAAP | $4.31 | $3.99 | $8.33 | $6.48 Non-GAAP | $4.73 | $4.52 | $9.21 | $8.58”
  • Operating income: “GAAP operating income | $1,246.9 | $1,151.1 | $2,385.0 | $1,781.2 Stock-based compensation expense | 170.2 | 167.3 | 336.6 | 333.4”
  • TRIKAFTA/KAFTRIO: “TRIKAFTA/KAFTRIO | $2,497.2 | $2,551.1 | $4,851.9 | $5,086.6 ALYFTREK | 573.6 | 156.8 | 998.0 | 210.7”
  • ALYFTREK: “ALYFTREK | 573.6 | 156.8 | 998.0 | 210.7 Other CF product revenues (1) | 137.1 | 193.7 | 273.0 | 349.0”
  • CASGEVY: “second quarter 2026 CASGEVY revenue of $76 million, representing 78% quarter-over-quarter sequential growth and 151% growth compared to the second quarter of 2025”
  • JOURNAVX: “second quarter 2026 JOURNAVX revenue of $50 million, representing 71% quarter-over-quarter sequential growth and more than quadrupling compared to $12 million in the second quarter of 2025”
  • JOURNAVX prescriptions filled: “In the second quarter and first six months of 2026, approximately 535,000 and approximately 900,000 prescriptions, respectively, have been filled for JOURNAVX across the hospital and retail settings.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$3.3B+12.5%+11.6%
Operating income$1.2B+8.3%+9.6%
Net income$1.1B+6.5%+6.6%
Diluted EPS$4.31+8.0%+7.2%
Free cash flow$1.0B+9.3%−21.7%
Operating margin37.4%−1.4 pts−0.7 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Total revenuefull year 2026$13.1 billion to $13.2 billion
Non-CF product revenuefull year 2026$500 million or more
Combined GAAP R&D, AIPR&D and SG&A expensesfull year 2026$6.3 billion to $6.45 billion
Combined non-GAAP R&D, AIPR&D and SG&A expensesfull year 2026$5.65 billion to $5.75 billion
Non-GAAP effective tax ratefull year 202619.5% to 20.5%

Key takeaways

  1. Crinetics deal adds rare endocrine as fifth pillar

    Vertex agreed to buy Crinetics for $85.00 per share in cash, about $8.8 billion net of cash acquired, with closing expected in the third quarter of 2026. Its guidance excludes the deal and will be updated after closing.

  2. ALYFTREK is displacing TRIKAFTA in cystic fibrosis

    ALYFTREK reimbursement reached 25 countries after four additions in the quarter, and Phase 3 data in children 2 to 5 led to global submissions. Vertex also signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for patients 6 and older.

  3. CASGEVY expands to children as access widens

    The FDA approved CASGEVY for ages 2 and older, 53 days after filing, and Germany granted reimbursement for patients 12 and older. CASGEVY is approved in 39 countries, and gentler conditioning programs aim to broaden eligibility further.

  4. Povetacicept sets up Vertex's nephrology launch

    The FDA accepted the IgAN accelerated-approval BLA with a PDUFA date of November 30, 2026. Vertex is also running Phase 3 work in primary membranous nephropathy and a Phase 2 study in generalized myasthenia gravis.

Charts

Revenue$3.3B+12.5% y/yQ2 2026
Q4 2024: $2.9B (worked out from the annual figure)Q4 ’24$2.9BQ1 2025: $2.8BQ1 ’25$2.8BQ2 2025: $3.0BQ2 ’25$3.0BQ3 2025: $3.1BQ3 ’25$3.1BQ4 2025: $3.2B (worked out from the annual figure)Q4 ’25$3.2BQ1 2026: $3.0BQ1 ’26$3.0BQ2 2026: $3.3BQ2 ’26$3.3BQ3 2026: $3.4BQ3 ’26$3.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.9B *
Q1 2025$2.8B
Q2 2025$3.0B
Q3 2025$3.1B
Q4 2025$3.2B *
Q1 2026$3.0B
Q2 2026$3.3B
Q3 2026$3.4B
Diluted EPS (GAAP)$4.31+8.0% y/yQ2 2026
Q1 2025: $2.49Q1 ’25$2.49Q2 2025: $3.99Q2 ’25$3.99Q3 2025: $4.20Q3 ’25$4.20Q1 2026: $4.02Q1 ’26$4.02Q2 2026: $4.31Q2 ’26$4.31Q3 2026: $2.56Q3 ’26$2.56
Data
Q1 2025$2.49
Q2 2025$3.99
Q3 2025$4.20
Q1 2026$4.02
Q2 2026$4.31
Q3 2026$2.56

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin37.4%−1.4 pts y/yQ2 2026
Q4 2024: 35.2%Q4 ’2435.2%Q1 2025: 22.7%Q1 ’2522.7%Q2 2025: 38.8%Q2 ’2538.8%Q3 2025: 38.6%Q3 ’2538.6%Q4 2025: 37.8%Q4 ’2537.8%Q1 2026: 38.1%Q1 ’2638.1%Q2 2026: 37.4%Q2 ’2637.4%Q3 2026: 20.7%Q3 ’2620.7%
Data
Q4 202435.2%
Q1 202522.7%
Q2 202538.8%
Q3 202538.6%
Q4 202537.8%
Q1 202638.1%
Q2 202637.4%
Q3 202620.7%
Free cash flow$1.0B+9.3% y/yQ2 2026
Q4 2024: $492.0MQ4 ’24$492.0MQ1 2025: $778.2MQ1 ’25$778.2MQ2 2025: $927.4MQ2 ’25$927.4MQ3 2025: $1.1BQ3 ’25$1.1BQ4 2025: $348.6MQ4 ’25$348.6MQ1 2026: $1.3BQ1 ’26$1.3BQ2 2026: $1.0BQ2 ’26$1.0BQ3 2026: $545.8MQ3 ’26$545.8M
Data
Q4 2024$492.0M
Q1 2025$778.2M
Q2 2025$927.4M
Q3 2025$1.1B
Q4 2025$348.6M
Q1 2026$1.3B
Q2 2026$1.0B
Q3 2026$545.8M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is Vertex buying from Crinetics, and when will it close?

Vertex agreed to acquire Crinetics for $85.00 per share in cash, about $10.0 billion in equity value or $8.8 billion net of cash acquired, adding rare endocrine diseases as a fifth pillar. Closing is expected in the third quarter of 2026, and Vertex will update guidance afterward.

How are Vertex's newer CF medicine and non-CF products performing?

ALYFTREK is now reimbursed in 25 countries and drove new CF patient initiations. CASGEVY and JOURNAVX are growing from small bases, and Vertex expects $500 million or more in 2026 revenue from the two combined.

What is the status of povetacicept?

The FDA accepted the BLA for accelerated approval in IgAN with a PDUFA date of November 30, 2026. Vertex has also confirmed the Phase 3 dose in primary membranous nephropathy and is enrolling a Phase 2 study in generalized myasthenia gravis.

What key pipeline readouts is Vertex expecting?

Vertex expects VX-828 and VX-670 results in the second half of 2026 and AMPLIFIED data this fall. AMPLITUDE interim data in AMKD are due in early 2027, and updated timelines for the zimislecel and VX-017 diabetes programs are expected later this year.

Documents

SEC filing